aibio
Distress ·
Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million
The deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing.
ZVRA Zevra Therapeutics, Inc.
Zevra Therapeutics (ZVRA) news ZVRA lawsuit and settlement news
Latest Zevra Therapeutics news
- Mergers
Zevra Therapeutics closes $150 million sale of rare pediatric disease priority review voucher
Zevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025.
- Financings
Zevra Therapeutics agrees to sell priority review voucher for $150 million
The company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period.
What Zevra Therapeutics does
Zevra Therapeutics is a commercial-stage company with a late-stage pipeline focused on rare diseases. Its lead product, MIPLYFFA (arimoclomol), is FDA approved for use with miglustat for neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older. It is available through an expanded access program in France, Germany and other EU member states and in select territories outside Europe, and a marketing authorization application for it is under review by the European Medicines Agency. OLPRUVA (sodium phenylbutyrate) for oral suspension is commercially available in the United States for certain urea cycle disorders. Zevra acquired Acer Therapeutics in November 2023, which brought in celiprolol for vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen (COL3A1) mutation. Celiprolol is in a Phase 3 trial called DiSCOVER. The company is also developing KP1077, a serdexmethylphenidate candidate, for idiopathic hypersomnia and narcolepsy. AZSTARYS, developed on Zevra's Ligand Activated Technology platform, is FDA approved and partnered, and Zevra receives royalties and milestones on its net sales. The company plans to expand its pipeline through inorganic growth.
| Product or program | What it is | Stage |
|---|---|---|
| MIPLYFFA (arimoclomol) | Oral treatment used with miglustat for neurological manifestations of Niemann-Pick disease type C | FDA approved |
| OLPRUVA (sodium phenylbutyrate) | Oral suspension for certain urea cycle disorders | FDA approved |
| Celiprolol | Treatment for vascular Ehlers-Danlos syndrome with a COL3A1 mutation | Phase 3 |
| KP1077IH | Serdexmethylphenidate for idiopathic hypersomnia | Phase 3 trial ready |
| AZSTARYS | Serdexmethylphenidate and dexmethylphenidate for attention deficit and hyperactivity disorder | FDA approved and partnered |
Zevra Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | $83.2 million | -$105.5 million |
| Cash from operations | -$1.6 million | -$69.7 million |
| Cash and equivalents | $62.4 million | $33.8 million |
| Short-term investments | $128.6 million | $35.7 million |
Questions about Zevra Therapeutics
Is Zevra Therapeutics involved in a lawsuit?
Our latest story on this, dated Mar 16, 2026: "Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million". The story links the filing or release it is based on. Read the story.
Has Zevra Therapeutics settled a lawsuit?
Our latest story on this, dated Mar 16, 2026: "Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Zevra Therapeutics?
Zevra Therapeutics, Inc. trades under the ticker ZVRA on NASDAQ.
Where is Zevra Therapeutics listed?
Zevra Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1GDA; LS:A2QLX7; LSX:A2QLX7.
What is the SEC CIK of Zevra Therapeutics?
The SEC Central Index Key (CIK) for Zevra Therapeutics, Inc. is 1434647. Its filings are on SEC EDGAR.
How many shares does Zevra Therapeutics have outstanding?
59,383,781 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Zevra Therapeutics listed under?
Our directory records Zevra Therapeutics, Inc. under United States.
What does Zevra Therapeutics do?
Our directory classifies Zevra Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Zevra Therapeutics?
The ISIN recorded for Zevra Therapeutics, Inc. is US4884452065.
Does aibio.space cover Zevra Therapeutics?
aibio.space lists Zevra Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Zevra Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Zevra Therapeutics develop?
Zevra Therapeutics is a commercial-stage company with a late-stage pipeline focused on rare diseases. Its lead product, MIPLYFFA (arimoclomol), is FDA approved for use with miglustat for neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older.
What is MIPLYFFA (arimoclomol) from Zevra Therapeutics?
MIPLYFFA (arimoclomol): Oral treatment used with miglustat for neurological manifestations of Niemann-Pick disease type C Stage: FDA approved.
What is OLPRUVA (sodium phenylbutyrate) from Zevra Therapeutics?
OLPRUVA (sodium phenylbutyrate): Oral suspension for certain urea cycle disorders Stage: FDA approved.
Is Zevra Therapeutics profitable?
Zevra Therapeutics, Inc. reported net income of $83.2 million for the fiscal year ended Dec 31, 2025, and used $1.6 million of cash in operations, per its annual report to the SEC.
Investor discussion: Zevra Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,7.01,9.01). Source
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,8.01,9.01). Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Zevra Therapeutics, Inc.
- CIK
- 1434647
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ZVRA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Phone
- (888) 958-1253
- Shares outstanding
- 59,383,781 as of 2026-07-31 (10-Q filed 2026-08-05)
- Former names
- KEMPHARM, INC; KEMPHARM INC
Recent filings
Listing details
- Company
- Zevra Therapeutics, Inc.
- Ticker
- ZVRA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US4884452065
- Other listed symbols
- GETTEX:1GDA; LS:A2QLX7; LSX:A2QLX7
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction